Positive Nachrichten bei Encysive Ph., +42 % heute

Hier die News..., Canadian Health Authority Approves THELIN (Sitaxsentan Sodium) for Pulmonary Arterial Hypertension Wednesday May 30, 5:46 pm ET First Selective Endothelin A Receptor Antagonist, First Once-Daily Oral Treatment HOUSTON, May 30, 2007 (PRIME NEWSWIRE) -- Encysive Pharmaceuticals (NasdaqGM:ENCY - News) today announced that Health Canada's Therapeutic Products Directorate has approved THELIN(tm) (sitaxsentan sodium) 100 mg tablets. ADVERTISEMENT THELIN is indicated for the treatment of primary pulmonary arterial hypertension (PAH) and pulmonary hypertension secondary to connective tissue disease, in patients with World Health Organization (WHO) functional class III who have not responded to conventional therapy. THELIN is also indicated in patients with WHO functional class II who did not respond to conventional therapy and for whom no appropriate alternative can be identified. THELIN is the first selective endothelin A receptor antagonist (ETRA) available, and [mehr]

aktiencheck.de - Forum - ENCYSIVE PHARMACEUTICALS INC

Positive Nachrichten bei Encysive Ph., +42 % heute